Acute lymphoblastic leukemia (ALL) accounts for approximately 20% of all acute leukemia seen in adults, and is the single most common cancer diagnosed during childhood. Cure rates have improved significantly for children who receive intensive chemotherapy, but the prognosis for adults remains poor. Allogeneic hematopoietic stem cell transplantation (HCT) is the salvage treatment of choice for children with relapsed ALL who have appropriate donors and is increasingly being used to treat adults in first remission. Advances in donor selection and supportive care have improved the outcome for patients with ALL undergoing allogeneic HCT, and leukemia relapse or complications related to graft-versus-host disease (GVHD) have emerged as the most common causes of treatment failure. In principle, targeting malignant cells by adoptive T cell therapy could provide an approach to therapy that would have negligible toxicity to normal cells. This project seeks to promote the immunologic clearance of leukemic cells after HCT without aggravating GVHD by the adoptive transfer of T cells that are engineered to express a chimeric antigen receptor (CAR) specific for the CD19 molecule on ALL stem and progenitor cells. Recent collaborative work by the Co- Principal Investigators in a nonhuman primate model has demonstrated that virus-specific T cells derived from the central memory (TCM) subset of cells have the ability to persist long-term in vivo and establish a reservoir of functional T cell memory. In preliminary work, we have developed reagents necessary to arm human central memory T cells specific for cytomegalovirus (CMV) pp65 with a CD19- specific CAR. In this project, we will optimize the cell processing methods for clinical application and conduct a clinical trial in which "bi-specific" T-cells will be adoptively transferred following HCT to promote an antileukemic effect.
The specific aims are:
Aim 1. To determine the safety and anti-tumor activity of adoptive therapy with donor TCM-derived bi-specific (CMVpp65xCD19) CD8+ TE clones for patients with CD19+ ALL following HLA matched allogeneic HCT.
Aim 2. To evaluate novel CD19-specific CAR vectors that encode a marker for rapid selection of transduced T cells and a costimulatory domain in tandem with the CD36 chain.
The majority of adults and a significant fraction of children that develop acute lymphoblastic leukemia (ALL) will die of progressive disease. The studies in this application will evaluate adoptive T cell therapy for ALL as an adjunct to hematopoietic stem cell transplantation using T cells that have an innate capacity to persist in vivo and are engineered to recognize a molecule expressed on the earliest leukemia progenitors. If this therapy safely eliminates residual ALL, this will improve the outcome of hematopoietic stem cell transplantation and provide opportunities to reduce the intensity of the preparative regimen and employ this therapy in the non-transplant setting.
|Jensen, Michael C; Riddell, Stanley R (2014) Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev 257:127-44|
|Bleakley, Marie; Heimfeld, Shelly; Jones, Lori A et al. (2014) Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells. Biol Blood Marrow Transplant 20:705-16|
|Riddell, Stanley R; Sommermeyer, Daniel; Berger, Carolina et al. (2014) Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J 20:141-4|
|McGoldrick, Suzanne M; Bleakley, Marie E; Guerrero, Abraham et al. (2013) Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo. Blood 121:2796-803|
|Green, Margaret L; Leisenring, Wendy M; Xie, Hu et al. (2013) CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122:1316-24|
|Riddell, Stanley R; Jensen, Michael C; June, Carl H (2013) Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond. Biol Blood Marrow Transplant 19:S2-5|
|Hudecek, Michael; Lupo-Stanghellini, Maria-Teresa; Kosasih, Paula L et al. (2013) Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 19:3153-64|
|Nauerth, Magdalena; Weiýýbrich, Bianca; Knall, Robert et al. (2013) TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer. Sci Transl Med 5:192ra87|
|Terakura, Seitaro; Yamamoto, Tori N; Gardner, Rebecca A et al. (2012) Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood 119:72-82|
|Wang, Xiuli; Chang, Wen-Chung; Wong, ChingLam W et al. (2011) A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118:1255-63|
Showing the most recent 10 out of 13 publications